Publications
223
Citations
2,206
Est. group size
~53
Recurring co-author estimate
Active years
12
Publishing since 2015
Nadia A. Lanman's research centers on cancer biology, with particular focus on pancreatic, prostate, and lung cancers, as well as broader work on drug resistance mechanisms and tumor microenvironment signaling. Her work spans molecular studies of tumor-promoting pathways (such as coagulation signaling and epigenetic regulators), drug repurposing (including antifungal and antiemetic drugs against resistant infections), and computational/bioinformatic approaches to genomic data analysis. This group applies a mix of laboratory experiments (e.g., mouse models, organoids) and data analysis methods (e.g., RNA-sequencing clustering) to understand cancer progression and treatment resistance.
Publication output has grown substantially over the last decade, rising sharply from single digits in 2017 to a peak of 67 in 2023, followed by continued high output through 2024-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Extravascular coagulation stabilizes pro-fibrotic stromal states via tumor-intrinsic PAR1 signaling in pancreatic ductal adenocarcinoma
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- AMPK‐Dependent Epigenetic Regulation of Metabolism Mediates the Anti‐Cancer Action of Pterostilbene in Hepatocellular Carcinoma
Molecular Nutrition & Food Research · 2025
- Abstract 1192: Selective sorting of tumor suppressive and oncogenic miRNAs into extracellular vesicles: Implications for cancer progression
Cancer Research · 2025
- Characterization of prostate macrophage heterogeneity, foam cell markers, and CXCL17 upregulation in a mouse model of steroid hormone imbalance
Scientific Reports · 2024
- Lansoprazole interferes with fungal respiration and acts synergistically with amphotericin B against multidrug-resistant <i>Candida auris</i>
Emerging Microbes & Infections · 2024
- Overcoming amphotericin B resistance in <i>Candida auris</i> using the antiemetic drug rolapitant
Antimicrobial Agents and Chemotherapy · 2024
- KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development
Oncogene · 2024
- Pterostilbene Targets Hallmarks of Aging in the Gene Expression Landscape in Blood of Healthy Rats
Molecular Nutrition & Food Research · 2024
- Response to the letter to the editor: Lansoprazole interferes with fungal respiration and acts synergistically with amphotericin B against multidrug-resistant <i>Candida auris</i> *
Emerging Microbes & Infections · 2024
- Human prostate organoid generation and the identification of prostate development drivers using inductive rodent tissues
Development · 2023
- Nonparametric clustering of <scp>RNA</scp>‐sequencing data
Statistical Analysis and Data Mining The ASA Data Science Journal · 2023
- Abstract 4752: Loss of the methyltransferase KMT5C drives resistance to tyrosine kinase inhibitors via H4K20me3 regulation in non-small cell lung cancer
Cancer Research · 2023
- Supplementary Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion
2023
- Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion
2023
- Data from Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET
2023
- bioRxiv (Cold Spring Harbor Laboratory)×28
- Cancer Research×16
- Frontiers in Immunology×4
- Scientific Reports×4
- Proceedings of the National Academy of Sciences×3
- Bozhi Liu
Medicine · Purdue University West Lafayette
- Jason A. Hanna
Medicine · Purdue University West Lafayette
- Annaleigh Benton
Medicine · Purdue University West Lafayette
- Ant Murphy
Medicine · Purdue University West Lafayette
- Claire M. Pfeffer
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile